Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-750

You must be one of sectors lost sheep. you’ve been brainwashed by bias. It was never built for large scale, success was its problem. They needed to re-tool to handle a larger scale than foreseen. Unlucky a batch was found not up to standard at this important juncture. Which sounds bad, yet, clearly, markers are traceable. Think about that point and the wider fear mongering about variability. You can’t have good trial outcomes if the product is all over the place. As if we can only manufacture a few hundred doses, like sectors claims. The penny has finally dropped on that fool. If that’s the case we’ll all be in a class action against the company. If anyone thinks we can only manufacture a few hundred doses a year and still bothering to invest and read the HC board needs their head read or needs to confess that their posts are intended to fool others. As if the MSB juggernaut is hurtling towards approval for massive indications and not be able to manufacture at scale is one strange outlook. Either MSB is the perfect con or they will deliver on their promises. To date MSB have delivered and are highly trusted. We are naturally disposed to finding negatives and fear, these are hard to find with MSB.